Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Severity and number of adverse events related to escalating doses of MM-141
Determine the Phase II dose based either on the maximum tolerated dose (MTD) or recommended dose in patients with advanced solid malignancies.
United States: Food and Drug Administration
|Georgia Cancer Specialists||Decatur, Georgia 30033|
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|
|Karmanos Cancer Institute||Detroit, Michigan 48201|